Vivesto
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
VIVE | ST
Overview
Corporate Details
- ISIN(s):
- SE0000722365 (+4 more)
- LEI:
- 5493003TZPR4B7QO9L49
- Country:
- Sweden
- Address:
- Box 3061, 169 03 SOLNA
- Website:
- https://www.vivesto.com/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Vivesto is a specialty pharmaceutical company focused on developing novel treatment options for patients with advanced and hard-to-treat cancers. The company's strategy involves advancing a portfolio of projects to address significant unmet medical needs in both human and veterinary oncology. Vivesto utilizes proprietary drug delivery technologies, such as its XR-17 platform, to improve the formulation and intravenous administration of established and new drugs. Key activities include the development and global out-licensing of its proprietary drug candidates, including products like Apealea and the veterinary candidate Paccal Vet. Formerly known as Oasmia, the company is dedicated to improving survival rates and the quality of life for cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-12 08:00 |
Interim Report
|
Swedish | 640.9 KB | ||
| 2025-05-08 10:30 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Vivesto AB
|
Swedish | 54.9 KB | ||
| 2025-05-08 10:30 |
Post-Annual General Meeting Information
Report from Annual General Meeting in Vivesto AB
|
English | 54.6 KB | ||
| 2025-05-08 08:00 |
Quarterly Report
|
Swedish | 612.7 KB | ||
| 2025-03-18 07:15 |
M&A Activity
Vivesto licenses Apealea to China’s Zhida Pharmaceutical
|
English | 64.5 KB | ||
| 2025-03-18 07:15 |
Regulatory News Service
Vivesto utlicensierar Apealea till kinesiska Zhida Pharmaceutical
|
Swedish | 64.9 KB | ||
| 2025-02-20 08:00 |
Earnings Release
|
Swedish | 935.6 KB | ||
| 2024-11-21 08:00 |
Quarterly Report
|
Swedish | 3.4 MB | ||
| 2024-11-07 10:54 |
M&A Activity
Vivesto signs Apealea option agreement with Zhida Pharmaceutical
|
English | 63.9 KB | ||
| 2024-11-07 10:54 |
Regulatory News Service
Vivesto ingår optionsavtal för Apealea med Zhida Pharmaceutical
|
Swedish | 64.3 KB | ||
| 2024-08-22 08:00 |
Interim Report
|
Swedish | 917.1 KB | ||
| 2024-05-23 10:48 |
Post-Annual General Meeting Information
Report from Annual General Meeting in Vivesto AB
|
English | 55.7 KB | ||
| 2024-05-23 10:48 |
Post-Annual General Meeting Information
Kommuniké från årsstämma i Vivesto AB
|
Swedish | 55.7 KB | ||
| 2024-05-23 08:00 |
Quarterly Report
|
Swedish | 900.5 KB | ||
| 2024-04-23 08:05 |
Annual Report
|
Swedish | 13.4 MB |
Automate Your Workflow. Get a real-time feed of all Vivesto filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Vivesto via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2020-06-18 | Sven Rohmann | Other | Sell | 80,000 | 499,614.08 SEK |
| 2020-06-18 | Sven Rohmann | Other | Sell | 77,000 | 492,724.39 SEK |
| 2020-06-18 | Sven Rohmann | Other | Sell | 77,000 | 486,655.63 SEK |
| 2020-06-18 | Sven Rohmann | Other | Sell | 77,000 | 476,656.95 SEK |
